Free Trial

UiPath (NYSE:PATH) Shares Down 2.8%

UiPath Inc. (NYSE:PATH - Get Free Report) was down 2.8% during mid-day trading on Monday . The company traded as low as $20.07 and last traded at $20.12. Approximately 3,313,244 shares changed hands during trading, a decline of 63% from the average daily volume of 8,982,307 shares. The stock had previously closed at $20.71.

Analysts Set New Price Targets

A number of research analysts have issued reports on PATH shares. Barclays lifted their price objective on UiPath from $23.00 to $25.00 and gave the company an "equal weight" rating in a report on Friday, March 15th. Bank of America lifted their price objective on UiPath from $26.00 to $30.00 and gave the company a "buy" rating in a report on Thursday, March 14th. KeyCorp started coverage on UiPath in a report on Monday, April 8th. They issued an "overweight" rating and a $27.00 price target for the company. Mizuho lifted their price target on UiPath from $22.00 to $25.00 and gave the company a "neutral" rating in a report on Thursday, March 14th. Finally, Morgan Stanley lifted their price target on UiPath from $17.00 to $25.00 and gave the company an "equal weight" rating in a report on Thursday, March 14th. Nine research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat, UiPath currently has an average rating of "Moderate Buy" and an average price target of $27.41.

Read Our Latest Analysis on UiPath


UiPath Trading Down 5.9 %

The business has a 50 day moving average of $23.24 and a 200-day moving average of $21.46. The firm has a market capitalization of $11.09 billion, a P/E ratio of -114.61 and a beta of 0.96.

UiPath (NYSE:PATH - Get Free Report) last posted its earnings results on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.04) by $0.10. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. The business had revenue of $405.25 million during the quarter, compared to analysts' expectations of $383.32 million. On average, analysts anticipate that UiPath Inc. will post -0.04 EPS for the current fiscal year.

Insiders Place Their Bets

In other UiPath news, CFO Ashim Gupta sold 40,000 shares of the company's stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $21.66, for a total transaction of $866,400.00. Following the completion of the transaction, the chief financial officer now owns 660,762 shares of the company's stock, valued at approximately $14,312,104.92. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders sold a total of 72,000 shares of company stock valued at $1,591,360 in the last quarter. 31.03% of the stock is currently owned by insiders.

Institutional Investors Weigh In On UiPath

Several large investors have recently made changes to their positions in PATH. Mark Sheptoff Financial Planning LLC bought a new position in UiPath during the 4th quarter worth $25,000. HighMark Wealth Management LLC bought a new position in UiPath during the 4th quarter worth $27,000. Tyler Stone Wealth Management bought a new position in UiPath during the 2nd quarter worth $28,000. Cypress Capital Management LLC WY bought a new position in shares of UiPath in the fourth quarter worth $29,000. Finally, Fifth Third Bancorp increased its position in shares of UiPath by 2,005.3% in the third quarter. Fifth Third Bancorp now owns 2,000 shares of the healthcare company's stock worth $34,000 after purchasing an additional 1,905 shares during the period. Institutional investors and hedge funds own 62.50% of the company's stock.

UiPath Company Profile

(Get Free Report)

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.

Featured Stories

Should you invest $1,000 in UiPath right now?

Before you consider UiPath, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UiPath wasn't on the list.

While UiPath currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Featured Articles and Offers

Search Headlines: